
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health is fundamentally attractive because it combines market leadership in liquid biopsy with multiple growth engines in Guardant360, Reveal, and Shield, while its underpenetrated cancer-testing markets still offer meaningful room for adoption. Recent catalysts materially de-risk the story: Q1’26 revenue rose 48% year over year to $302 million, oncology test volumes increased 47%, and the company held $1.2 billion of cash, while UHC’s Shield coverage effective August 1, 2026 and ACS guideline inclusion should expand both volumes and reimbursement. With 2026 guidance lifted to $1.30-$1.32 billion and continued ASP upside from FDA approval, ADLT prospects, and broader payer coverage, the stock’s positive outlook is anchored in durable growth, improving margins, and a long runway for commercialization.
Bears say
Guardant Health is viewed negatively because its core Guardant360 franchise still represents more than 60% of sales, yet investors have already seen sensitivity to any growth deceleration and recent 30% year-over-year volume growth is unlikely to be sustained. The company also faces a tougher competitive backdrop in MRD and screening, where Reveal competes against more established tissue-informed approaches and Shield’s addressable market may be smaller than expected without clearer USPSTF support. Financially, Guardant has burned more than $200 million in cash in each of the past two years, burn accelerated in the most recent quarter, and any slippage from management’s Q4 2027 breakeven target could pressure the balance sheet.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Guardant Health Inc (GH) Forecast
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares